The biggest stories of the day delivered to your inbox.

Reviva Pharmaceuticals Holdings Inc. (NASDAQ: RVPH) on Tuesday announced a regulatory update following a pre-New Drug Application (pre-NDA) meeting with the U.S. Food and Drug Administration (FDA).

Share your feedback and you could win $50. Never miss a story with The Brief, our free newsletter. Keep tabs on Texas politics and policy with our morning newsletter. The Texas Tribune Independent ...

(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) and Quantum Leap Healthcare Collaborative, on Friday, announced a collaboration to evaluate TTX-MC138 in a Phase 2a dose-expansion trial. TTX-MC138, ...

The Independent National Electoral Commission (INEC) announced on Wednesday that approximately 9.891 million Nigerians have pre-registered online in the ongoing Continuous Voter Registration (CVR) ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Brooklyn White Brooklyn White is a writer who has been playing Phase 10 for ...

In freshman year, Amav C. Khambete ’27 learned how to think like a scientific researcher. For Khambete, who had a robust high school science education, some of the introductory life science courses ...

Background: Early identification of seizures in children is important for safety, intervention success, and quality of life improvement, because many children are unable to reliably communicate sensed ...

On May 29, 1975, Steve Prefontaine ran 12.5 laps at Hayward Field in 13:23.8 — less than two seconds off his own American record in the 5K. History remembers it as Pre’s final race. Just hours later, ...

Like much in life, the difference between detonation and pre-ignition, and their effects, comes down to timing. Both refer to a situation when an engine's fuel/air mixture combusts at the wrong time, ...

(RTTNews) - KALA Bio, Inc. (KALA) on Monday announced that its CHASE Phase 2b study of KPI-012 for the treatment of persistent corneal epithelial defect (PCED) did not meet the primary endpoint of ...